ACB vs IIPR: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ACB and IIPR share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ACB and IIPR exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Aurora Cannabis is a Canadian licensed cannabis producer that has spent the past several years reinventing itself. Once one of the most hyped names of the 2018-2019 cannabis boom, it has since exited low-margin Canadian consumer (recreational) cannabis and non-core operations to concentrate on global medical cannabis, which carries higher and more durable margins. In its fiscal 2026 (ended March 31, 2026) the company reported record medical results: global medical net revenue grew sharply, international medical revenue rose even faster (led by Germany and Poland), and adjusted EBITDA and free cash flow were positive, a real shift from years of cash burn. On a GAAP basis, however, Yahoo Finance data show fiscal 2026 revenue of about 321 million and a net loss of about 122 million (Canadian dollars), with large losses in two quarters. International medical, its highest-margin segment, now makes up a majority of medical revenue. To feed that demand, Aurora acquired Safari Flower Company, an EU-GMP certified European cultivator, completed the divestiture of its controlling stake in Bevo Agtech in February 2026, and in October 2026 finished an expansion of its European EU-GMP facility that it says more than doubles expected annual flower output.

Full ACB guide

Innovative Industrial Properties, Inc. (NYSE: IIPR) is a real estate investment trust that pioneered the cannabis-focused, sale-leaseback model in the United States. It buys industrial and greenhouse cultivation and processing facilities from state-licensed cannabis operators and leases them back on long-term, triple-net leases, meaning tenants are responsible for property taxes, insurance, and maintenance. Because federally regulated banks have historically been wary of lending to cannabis companies, IIPR stepped in as a specialized source of real estate capital, and rent from these leases is its primary source of income. As of early 2026 the company owned roughly 110 properties totaling around 8.9 million rentable square feet across about 19 states, leased to a few dozen tenants, and has begun describing itself as a diversified REIT with some interest beyond cannabis.

Full IIPR guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ACB drivers: International medical cannabis growth; The Curaleaf bid and strategic review.
• IIPR drivers: High dividend and income appeal; Tenant recovery and re-leasing.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The central risk is Aurora's capital-structure history: repeated equity raises and a cumulative reverse-split history (roughly 1-for-120 over time) have destroyed per-share value, and further dilution would do so again. For IIPR, the dominant risk is tenant concentration and credit quality: IIPR leases to a limited number of cannabis operators, and defaults by its largest tenant and others directly threaten rental income and the dividend, which has at times been uncovered by funds from operations.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ACB if you believe its drivers more; IIPR if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ACB and IIPR guides.

ACB. Aurora trades below book value and under one times sales, a discount that tracks its losses and dilution history, but in October 2026 the price is also being set by the Curaleaf bid: the shares sit about 20% below the roughly $5 headline offer, since most of that value is in Curaleaf stock and the board opposes it. Be cautious with per-share comparisons across time given the reverse-split history, and check the current share count, cash position, and the status of the offer directly in filings. Fiscal second-quarter results are expected in early November 2026.

IIPR. Figures are approximate, tied to the asOf date, and should be verified against the latest filings before acting. For a REIT, the metrics that matter most are funds from operations (FFO) and adjusted FFO relative to the dividend, plus occupancy and rent collection, rather than a standard P/E ratio; at roughly 12 times earnings and below book value the shares are priced for continued tenant stress. A ~14% dividend yield reflects elevated perceived risk, not just generosity: the market is pricing in the chance of a cut, so treat the headline yield with caution and check the latest FFO and payout figures. Analyst views are mixed, with a hold consensus and a mean target near ~$61, while Stifel initiated at Buy ($56.25) and Huntington at Outperform ($60) in October 2026.

Headline figures (approximate, October 2026): ACB shows market cap ~$252M at ~$3.98 a share (Oct 16, 2026), revenue (ttm) ~314M (Canadian dollars), down ~9% YoY in the latest quarter, net income (ttm) ~-52M; Q1 FY2027 net loss only ~-4M, eps (latest quarter) ~-$0.07 vs ~-$0.21 estimate; IIPR shows revenue (ttm) ~$264M; Q2 2026 ~$63.3M, net income and eps (ttm) ~$126M, ~$4.42 per share; Q2 2026 EPS ~$0.96 vs ~$1.02 expected, quarterly dividend $1.90 per share ($7.60 a year), ~14.3% yield at ~$52.74, dividend coverage Payout ~172% of trailing EPS; coverage hinges on resolving defaults, re-leasing and FFO.

ACB and IIPR are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ACB and IIPR exposure against your real portfolio. It is not an investment adviser.